Status:
NOT_YET_RECRUITING
Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions
Lead Sponsor:
Centre Hospitalier Universitaire de la Réunion
Collaborating Sponsors:
Institut Paoli-Calmettes
Conditions:
Allogeneic Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT ...
Eligibility Criteria
Inclusion
- patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome
- candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ;
- Residing in Reunion Island
- Age \>18 year old;
- who accept or not allogeneic hematopoietic
- Able to complete a questionnaire
Exclusion
- Opposition to participation and collection of their data
- Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05327673
Start Date
July 1 2022
End Date
March 1 2027
Last Update
April 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de la Réunion
Saint-Pierre, France, 97448